CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of “Moderate Buy” by Brokerages

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $8.3571.

A number of research analysts recently issued reports on CAMP shares. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Leerink Partners increased their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Rodman & Renshaw began coverage on shares of CAMP4 Therapeutics in a report on Tuesday, April 14th. They set a “buy” rating and a $7.00 target price for the company. Finally, Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st.

Hedge Funds Weigh In On CAMP4 Therapeutics

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth about $61,000. Jefferies Financial Group Inc. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth about $70,000. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth about $86,000. OMERS ADMINISTRATION Corp acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth about $115,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth about $115,000.

CAMP4 Therapeutics Stock Performance

Shares of CAMP stock opened at $4.13 on Monday. The company has a market capitalization of $214.47 million, a P/E ratio of -1.75 and a beta of 0.08. The company’s 50 day moving average price is $4.32 and its two-hundred day moving average price is $4.71. CAMP4 Therapeutics has a 52 week low of $1.30 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Analysts forecast that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.